{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008065","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.590710+00:00","generated_at":"2026-05-16T00:27:31.910053+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization","bullets":["Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.","Shareholders authorized reverse stock split at ratio between 1:25 and 1:85, with exact ratio set by Board in its discretion.","Both proposals passed with strong support: 147.8M for plan amendment; 176.3M for reverse split (no broker non-votes on split).","182.4 million shares were represented at the special meeting, ~90.5% of outstanding 201.5M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008065","json":"https://secwatch.observer/filing/0001493152-26-008065.json","markdown":"https://secwatch.observer/filing/0001493152-26-008065.md","text":"https://secwatch.observer/filing/0001493152-26-008065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315226008065/0001493152-26-008065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315226008065/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:27:31.910053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}